EUSA Pharma has launched a new artificial saliva preparation, Caphosol, for the management of dry mouth and oropharynx as well as mucositis due to radiation or high-dose chemotherapy.

Caphosol comprises two separately packaged aqueous solutions, a phosphate solution and a calcium solution which, when combined, form a solution supersaturated with respect to both calcium and phosphate ions. It is an electrolyte solution designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx.

Caphosol can be used four to 10 times daily and patients should avoid eating or drinking for at least 15 minutes after use.

View Caphosol drug record

Further information: EUSA Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases